{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T09:17:16Z","timestamp":1789377436571,"version":"build-2803163510"},"publisher-location":"Chichester, UK","reference-count":186,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd001190","type":"reference-entry","created":{"date-parts":[[2003,11,21]],"date-time":"2003-11-21T03:16:04Z","timestamp":1069384564000},"source":"Crossref","is-referenced-by-count":71,"title":["Donepezil for dementia due to Alzheimer's disease"],"prefix":"10.1002","author":[{"given":"JS","family":"Birks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2003,7,21]]},"reference":[{"issue":"2","key":"10.1002\/14651858.CD001190-BIB1|cit1","first-page":"251","article-title":"Late phase II clinical study of acetyl cholinesterase inhibitor E2020 in patients with Alzheimer-type dementia","volume":"26","author":"Homma","year":"1998","journal-title":"Clinical Evaluation"},{"key":"10.1002\/14651858.CD001190-BIB2|cit2","doi-asserted-by":"crossref","unstructured":"Homma A, Takeda M, Imai Y, Udaka F, Hasegawa K, Kameyama M, Nishimura T, Tohgi H, Yamazaki E, Totsuka S, Otani K, Kawakatsu S, Takeuchi H, Kubo K, Maruki Y, Ueki A, Otuska M, Araki T, Asai K, Abe T, Someya Y, Hirai S, Kato M, Mimura M, Hirasawa H, Koyama K, Isse K, Uno M, Asada T, Takayama Y, Tanaya K, Odagiri T, Ishii T, Aoba A, Kosaka A, Murasaki M, Otani Y, Shinohara Y, Tachikawa H, Imai N, Hamanaka T, Nakanishi M, Ojika K, Fujita S, Yamada K, Kamimoto K, Yamada T, Takada K, Uchida M, Watanabe Y, Takahashi N, Kurachi M, Suzuki M, Koshino Y, Kobayashi K, Jibiki I, Sugawara K, Isaki K, Fukutani Y, Kuzuhara S, Narita Y, Naito Y, Murai K, Matsuyama M, Fujimoto N, Narita M, Miyoshi K, Nakajima K, Mori S, Tada K, Nakamura Y, Ogihara T, Miki T, Imai T, Takahashi M, Nishimoto K, Yamamoto H, Yamamoto T, Moro E, Hashimoto M, Tanimukai S, Ikejiri Y, Morita Y, Terao A, Yasuda T, Funakawa I, Sasaki K, Fujisawa Y, Nakamura S, Katayama S, Yoshinaga J, Takahashi K, Nakashima K, Urakami K, Ishino H, Miyaoka T, Kobayashi S, Ikeda H, Inoue S, E2020 Study Group Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease: A 24-week, multicenter, double-blind, placebo-controlled study in Japan Dementia and Geriatric Cognitive Disorders 2000 299 313","DOI":"10.1159\/000017259"},{"key":"10.1002\/14651858.CD001190-BIB3|cit3","unstructured":"Friedhoff LT Ieni JR Rogers SL Pratt RD Donepezil provides long-term clinical benefits for patients with Alzheimer's Disease Proceedings of the 21st Collegium Internationale Neuro psychopharmacologicum;1998 Jul 12-16, Glasgow, Scotland 1998 ABSTRACT REF: PW11017 SR-HANDSRCH"},{"key":"10.1002\/14651858.CD001190-BIB4|cit4","unstructured":"Friedhoff LT Rogers SL Correlation between the clinical efficacy of donepezil HCL (E2020) and red blood cell (RBC) Acetylcholinesterase (ACHE) inhibition in patients with Alzheimer's disease Proceedings of the 98th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics; 1997 Mar 5-8, San Diego 1997 6 7"},{"key":"10.1002\/14651858.CD001190-BIB5|cit5","doi-asserted-by":"crossref","unstructured":"Rogers S Perdomo C Friedhoff L Clinical Benefits are Maintained During Long-term Treatment of Alzheimer's Disease with the Acetylcholinesterase Inhibitor, E2020 Proceedings of the 8th European College of Neuropsychopharmacology Congress; 1995 Sep 30-Oct 4, Venice 1995 SR-HANDSRCH","DOI":"10.1016\/0924-977X(95)90701-E"},{"key":"10.1002\/14651858.CD001190-BIB6|cit6","doi-asserted-by":"crossref","unstructured":"Rogers SL Doody RS Pratt RD Ieni JR Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study European Neuropsychopharmacology 2000 195 203","DOI":"10.1016\/S0924-977X(00)00067-5"},{"key":"10.1002\/14651858.CD001190-BIB7|cit7","unstructured":"Rogers SL Friedhoff LT E2020 improves cognition and quality of life in patients with mild to moderate Alzheimers Disease: results of a phase II trial Proceedings of the 46th Annual meeting of the American Academy of Neurology. 1994 May 1-7, Washington DC 1994 A165"},{"key":"10.1002\/14651858.CD001190-BIB8|cit8","first-page":"293","article-title":"The Efficacy and safety of Donepezil in patients with Alzheimer's disease: results of a US multicentre, randomised, double-blind, placebo-controlled trial","volume":"7","year":"1996","journal-title":"Dementia"},{"key":"10.1002\/14651858.CD001190-BIB9|cit9","series-title":"Proceedings of the 14th Annual Meeting of the American Association for Geriatric Psychiatry; 2001 Feb 23-26 San Francisco","article-title":"PET in AD: Donepezil HCl (E2020) maintains functional brain activity in patients with Alzheimer's disease: results of a 24-week study","author":"Tune","year":"2001"},{"key":"10.1002\/14651858.CD001190-BIB10|cit10","series-title":"Proceedings of the 151st Annual Meeting of the American Psychiatric Association; 1998 May 30- Jun 4, Toronto","first-page":"NR345","article-title":"Functional Brain Activity in Alzheimer's Disease","author":"Tune","year":"1998"},{"key":"10.1002\/14651858.CD001190-BIB11|cit11","unstructured":"Anon No title Eisai Inc"},{"key":"10.1002\/14651858.CD001190-BIB12|cit12","unstructured":"Anon No title Eisai Inc"},{"issue":"3","key":"10.1002\/14651858.CD001190-BIB13|cit13","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1001\/archneur.58.3.427","article-title":"Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease","volume":"58","year":"2001","journal-title":"Archives of Neurology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD001190-BIB14|cit14","first-page":"116","article-title":"Long-term safety and tolerability of donepezil: results from a phase iii extension trial of patients with mild to moderately severe alzheimer's disease","volume":"6","author":"Pratt","year":"1999","journal-title":"European Journal of Neurology"},{"key":"10.1002\/14651858.CD001190-BIB15|cit15","series-title":"Proceedings of the Sixth International Stockholm\/Springfield Symposium on Advances in Alzheimer Therapy; 2000 Apr 5-8, Stockholm","first-page":"133","article-title":"Donepezil new clinical trials support long term use","author":"Rogers","year":"2000"},{"key":"10.1002\/14651858.CD001190-BIB16|cit16","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1001\/archinte.158.9.1021","article-title":"Donepezil improves cognition and global function in Alzheimer disease","volume":"158","year":"1998","journal-title":"Arch Intern Med"},{"key":"10.1002\/14651858.CD001190-BIB17|cit17","series-title":"American Psychiatric Association 150th Annual Meeting, San Diego","article-title":"Donepezil (E2020) improves cognition and function in patients with mild to moderately severe Alzheimer's disease. Results from Phase III trials","author":"Rogers","year":"1997"},{"issue":"3","key":"10.1002\/14651858.CD001190-BIB18|cit18","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1001\/archneur.58.3.427","article-title":"Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease","volume":"58","year":"2001","journal-title":"Archives of Neurology"},{"key":"10.1002\/14651858.CD001190-BIB19|cit19","doi-asserted-by":"crossref","unstructured":"Feldman H\/\/GauthierS\/\/Hecker J\/\/Vellas B\/\/Subbiah P\/\/Whalen E\/\/Donepezil MSAD Study Investigators Group Erratum: a 24-week, randomized, double-blind study of donepezil in moderate to severe alzheimer's disease (neurology (2001) 57 (613-620)) Neurology 2001 2153","DOI":"10.1212\/WNL.57.4.613"},{"issue":"3","key":"10.1002\/14651858.CD001190-BIB20|cit20","first-page":"A100","article-title":"Donepezil lengthens time to loss of activities of daily living in patients with mild to moderate Alzheimer's disease - results of a preliminary evaluation. presented at the annual meeting of the American Academy of Neurology. Boston","volume":"48","author":"Friedhoff","year":"1997","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD001190-BIB21|cit21","first-page":"S9","article-title":"Donepezil maintains activities of daily living in patients with mild to moderately severe Alzheimer's disease: results of a retrospective analysis","volume":"4, Suppl 1","author":"Friedhoff","year":"1997","journal-title":"Eur J Neurology"},{"key":"10.1002\/14651858.CD001190-BIB22|cit22","doi-asserted-by":"crossref","unstructured":"Friedhoff LT Rogers SL Donepezil lengthens time to loss of activities of daily living and cognition in patients with mild to moderate Alzheimer's disease Proceedings of the 10th European College of Neuropsychopharmacology Congress; 1997 Sep 13-17, Vienna, Austria 1997 SR-HANDSRCH","DOI":"10.1016\/S0924-977X(97)88814-1"},{"key":"10.1002\/14651858.CD001190-BIB23|cit23","series-title":"Proceedings of the Sixth International Stockholm\/Springfield Symposium on Advances in Alzheimer Therapy; 2000 Apr 5-8, Stockholm","first-page":"133","article-title":"Donepezil new clinical trials support long term use","author":"Rogers","year":"2000"},{"key":"10.1002\/14651858.CD001190-BIB24|cit24","first-page":"A217 S14.001 AR","article-title":"E2020 produces both clinical, global and cognitive test improvement in patients with mild to moderately severe Alzheimer's disease: Results of a 30-week phase III trial","volume":"46","author":"Rogers","year":"1996","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD001190-BIB25|cit25","unstructured":"Rogers SL, Doody R, Mohs R, Friedhoff T, Donepezil Study Group E2020 (Aricept TM) improves global and cognitive function in patients with Alzheimer's Disease. Results of a 30-week trial unpublished paper 1996"},{"issue":"1","key":"10.1002\/14651858.CD001190-BIB26|cit26","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1212\/WNL.50.1.136","article-title":"A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease","volume":"50","year":"1998","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD001190-BIB27|cit27","unstructured":"Rogers SL Friedhoff LT Farlow MR Doody RS Mohs R Efficacy of donepezil in Alzheimer's disease: Fact or artifact? [Reply] Neurology 1999 218 9"},{"key":"10.1002\/14651858.CD001190-BIB28|cit28","doi-asserted-by":"crossref","unstructured":"Rogers SL Mohs RC Friedhoff LT Donepezil (E2020) improves cognition and function in patients with mild to moderately severe Alzheimer's disease. Results from Phase III trials American Psychiatric Association 150th Annual Meeting, San Diego 1997","DOI":"10.1016\/S0924-977X(97)88814-1"},{"key":"10.1002\/14651858.CD001190-BIB29|cit29","unstructured":"Bayer AJ, Rossor M, Hecker J, Gauthier S, Burns A, Petite H, Moller HJ, Rogers SL, Friedhoff LT, International Donepezil Study Group Donepezil improves functional activity in patients with Alzheimer's disease Proceedings of the 21st Collegium Internationale Neuro psychopharmacologicum; 1998 Jul 12-16, Glasgow, Scotland 1998 SR-HANDSRCH"},{"issue":"3","key":"10.1002\/14651858.CD001190-BIB30|cit30","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1159\/000017126","article-title":"The effects of donepezil in Alzheimer's disease - results from a multinational trial","volume":"10","year":"1999","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.1002\/14651858.CD001190-BIB31|cit31","unstructured":"Gauthier S Rosser M Hecker J Petite H Rogers S Mohr E Burns A Friedhoff LT Rogers S Donepezil Produces Both Clinical Global and Cognitive Test Improvement in Patients with Alzheimer's Disease Proceedings of the 151st Annual Meeting of the American Psychiatric Association; 1998 May 30-Jun 4, Toronto, Canada 1998 SR-HANDSRCH"},{"key":"10.1002\/14651858.CD001190-BIB32|cit32","unstructured":"Gauthier S Rossor M Hecker J Results from a multinational Phase III clinical trial of donepezil in Alzheimer's disease [abstract] [poster presentation at 5th International Geneva\/Springfield Symposium on Advances in Alzheimer therapy]"},{"key":"10.1002\/14651858.CD001190-BIB33|cit33","doi-asserted-by":"crossref","unstructured":"Pratt RD Gauthier S Burns A Perdomo CA Donepezil provides long-term clinical benefits for patients with Alzheimers Disease Proceedings of the World Alzheimer Congress; 2000 Jul 9-13, Washington 2000","DOI":"10.1016\/S0197-4580(00)82652-4"},{"key":"10.1002\/14651858.CD001190-BIB34|cit34","unstructured":"Anon No title Eisai Inc"},{"key":"10.1002\/14651858.CD001190-BIB35|cit35","unstructured":"Tariot P Cummings JL Katz IR Perdomo CA Whalen E Sovel MA Schwam EM Donepezil was well-tolerated and enhanced cognition in nursing home patients with alzheimer's disease Journal of the American Geriatrics Society 1999 S3"},{"key":"10.1002\/14651858.CD001190-BIB36|cit36","series-title":"International Psychogeriatrics","first-page":"134","article-title":"Age is not a barrier to donepezil treatment of Alzheimer's disease in the long-term care setting","author":"Tariot","year":"1999"},{"key":"10.1002\/14651858.CD001190-BIB37|cit37","doi-asserted-by":"crossref","unstructured":"Tariot PN Cummings JL Katz IR Mintzer J Perdomo CA Schwam EM Whalen E A randomised, double-blind, placebo-controlled study of the efficacy and safety of Donepezil in patients with Alzheimer's disease in the nursing home setting Journal of the American Geriatrics Society 2001 1590 9","DOI":"10.1111\/j.1532-5415.2001.49266.x"},{"key":"10.1002\/14651858.CD001190-BIB38|cit38","doi-asserted-by":"crossref","unstructured":"Mohs R Doody R Morris J Ieni J Perdomo C Pratt R Rogers S Donepezil preserves activities of daily living in alzheimer's disease patients: results from a one-year placebo-controlled functional survival study Neurology 2000 A415","DOI":"10.1016\/S0924-977X(99)80460-X"},{"key":"10.1002\/14651858.CD001190-BIB39|cit39","doi-asserted-by":"crossref","unstructured":"Mohs R Doody R Morris J Ieni J Rogers S Perdomo C Pratt R Donepezil preserves functional status and improves cognition in alzheimer's disease patients: results from a 1-year propective placebo-controlled study Journal of the American Geriatrics Society 2000 S46","DOI":"10.1016\/S0924-977X(99)80460-X"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD001190-BIB40|cit40","doi-asserted-by":"crossref","first-page":"S328","DOI":"10.1016\/S0924-977X(99)80460-X","article-title":"Donepezil preserves functional status in Alzheimer's disease patients: results from a 1-year prospective placebo-controlled attrition study","volume":"9","author":"Mohs","year":"1999","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD001190-BIB41|cit41","doi-asserted-by":"crossref","unstructured":"Mohs R Doody R Morris J Ieni JR Rogers SL Perdomo CA Pratt RD Donepezil preserves functional status in Alzheimer's disease patients: results from a 1-year prospective placebo-controlled study Proceedings of the Quality Research in Dementia Conference; 2000 Nov 19-22, London 2000","DOI":"10.1016\/S0924-977X(99)80460-X"},{"key":"10.1002\/14651858.CD001190-BIB42|cit42","doi-asserted-by":"crossref","unstructured":"Mohs RC, Doody RS, Morris JC, Ieni JR, Rogers SL, Perdomo C , Pratt RD, 312 Study Group A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients [Erratum] Neurology 2001 1942 http:\/\/www.lww.com","DOI":"10.1212\/WNL.57.3.481"},{"key":"10.1002\/14651858.CD001190-BIB43|cit43","doi-asserted-by":"crossref","unstructured":"Mohs RC Doody RS Morris JC Ieni JR Rogers SL Perdomo CA Pratt RD A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients Neurology 2001 481 8","DOI":"10.1212\/WNL.57.3.481"},{"key":"10.1002\/14651858.CD001190-BIB44|cit44","unstructured":"Mohs RC Doody RS Morris JC Leni JR Rogers SL Perdomo CA Pratt RD Donepezil preserves functional status in Alzheimer's disease Proceedings of the 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13-18, Chicago, Illionois 2000 SR-HANDSRCH"},{"key":"10.1002\/14651858.CD001190-BIB45|cit45","doi-asserted-by":"crossref","unstructured":"Pratt R Mohs R Doody R Morris J Rogers S Ieni J Perdomo C Donepezil preserves functional status in Alzheimer's disease patients results from a 1-year prospective placebo controlled functional study Proceedings of the 6th International Stockholm\/Springfield Symposium on Advances in Alzheimer Therapy; April 5-8, 2000; Stockholm, Sweden 2000 178","DOI":"10.1016\/S0924-977X(99)80460-X"},{"key":"10.1002\/14651858.CD001190-BIB46|cit46","series-title":"The 8th conference on Alzheimer's disease and related disorders, July 20-25, 2002, Stockholm, Sweden","first-page":"337","article-title":"Twelve week respone to cholinesterase inhibitors dose not predict future benefit the AD2000 trial experiance","author":"Bentham","year":"2002"},{"key":"10.1002\/14651858.CD001190-BIB47|cit47","unstructured":"Lendon CL Determination of respones to anticholinesterase therapy in the treatment of Alzheimer's disaese The 8th conference on Alzheimer's disease and related disorders, July 20-25, 2002, Stockholm, Sweden 2002 1287"},{"key":"10.1002\/14651858.CD001190-BIB48|cit48","unstructured":"Roberts N A reliable assessment of the efficacy and safety of donepezil and aspirin in Alzheimer's disease (AD2000) National Research Register 2001"},{"key":"10.1002\/14651858.CD001190-BIB49|cit49","unstructured":"Waghray S AD2000 A reliable assessment of the efficacy and safety of donepezil and aspirin in Alzheimer's disease National Research Register 2000 http:\/\/www.doh.gov.uk\/nrr.htm"},{"key":"10.1002\/14651858.CD001190-BIB50|cit50","unstructured":"Robert P, Lebert F, Goni S, Touchon J, Vincent S, ARIAL Study Investigators Collaborative Group The impact on caregiver distress of donepezil treatment of patients with mild Alzheimer's disease Proceedings of the Quality Research in Dementia; 19-22 November, 2000; London 2000"},{"key":"10.1002\/14651858.CD001190-BIB51|cit51","unstructured":"Robert PH, Lebert F, Goni S, Touchon J, ARIAL Study Investigators Collaborative Group The impact of caregiver distress of donepezil treatment of patients with mild alzheimer's disease Proceedings of the 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15-20, Washington DC 1999 SR-HANDSRCH"},{"key":"10.1002\/14651858.CD001190-BIB52|cit52","unstructured":"Feldman H Therapeutic benefits of acetylcholinesterase inhibitor therapy in the moderate to severe stage of alzheimer's disease Proceedings of the Sixth International Stockholm\/Springfield Symposium on Advances in Alzheimer Therapy; 2000 Apr 5-8, Stockholm 2000 59"},{"key":"10.1002\/14651858.CD001190-BIB53|cit53","doi-asserted-by":"crossref","unstructured":"Feldman H Gauthier S Hecker J Vellas B Hux M Emir B Subbiah P Mastery V Improved health outcomes with donepezil in moderate to severe Alzheimer's disease are associated with economic benefits The 8th conference on Alzheimer's disease and related disorders, July 20-25, 2002, Stockholm, Sweden 2002 285","DOI":"10.1017\/S104161020200858X"},{"key":"10.1002\/14651858.CD001190-BIB54|cit54","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1046\/j.1365-2389.2003.51260.x","article-title":"Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden","volume":"51","year":"2003","journal-title":"Journal of the American Geriatrics Society"},{"key":"10.1002\/14651858.CD001190-BIB55|cit55","doi-asserted-by":"crossref","unstructured":"Feldman H Gauthier S Hecker J Vellas B Subbiah P Whalen E Donepezil provides benefits in global function in moderate to severe Alzheimer's Disease Proceedings of the World Alzheimer Congress; 2000 Jul 9-13, Washington DC 2000","DOI":"10.1016\/S0197-4580(00)82641-X"},{"key":"10.1002\/14651858.CD001190-BIB56|cit56","doi-asserted-by":"crossref","unstructured":"Feldman H Gauthier S Hecker J Vellas B Subbiah P Whalen E Donepezil's benefits on cognition, global function, activities of daily living and behavior in patients with moderate to severe alzheimer's disease Proceedings of the Sixth International Stockholm\/Springfield Symposium on Advances in Alzheimer Therapy; 2000 Apr 5-8, Stockholm 2000 174","DOI":"10.1016\/S0197-4580(00)82641-X"},{"key":"10.1002\/14651858.CD001190-BIB57|cit57","unstructured":"Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E, Donepezil MSAD Study Group Benefits of Donepezil on global function, behavior, cognition and ADLs in patients with moderate to severe Alzheimer's disease Neurology 2000 A469"},{"key":"10.1002\/14651858.CD001190-BIB58|cit58","doi-asserted-by":"crossref","unstructured":"Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E, Donepezil MSAD Study Investigators Group A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease Neurology 2001 613 20","DOI":"10.1212\/WNL.57.4.613"},{"key":"10.1002\/14651858.CD001190-BIB59|cit59","doi-asserted-by":"crossref","unstructured":"Gauthier S Feldman H Hecker J Vellas B Emir B McGill PS Exploratory analysis of the effects af donepezil in moderate and severe Alzheimer's disease patients The 8th conference on Alzheimer's disease and related disorders, July 20-25, 2002, Stockholm, Sweden 2002 277","DOI":"10.1185\/030079902125001029"},{"key":"10.1002\/14651858.CD001190-BIB60|cit60","series-title":"Journal of the European College of Neuropsychopharmacology","first-page":"S359","article-title":"Effects of donepezil on behaviour and other domains in moderate to severe alzheimer's disease","author":"Gauthier","year":"2000"},{"key":"10.1002\/14651858.CD001190-BIB61|cit61","doi-asserted-by":"crossref","unstructured":"Gauthier S Feldman H Hecker J Vellas B Subbiah P Whalen E Benefits of Donepezil on performance of basic and instrumental activities of daily living in moderate to sever Alzheimer's Disease Proceedings of the World Alzheimer Congress; 2000 Jul 9-13, Washington DC 2000","DOI":"10.1016\/S0197-4580(00)82065-5"},{"key":"10.1002\/14651858.CD001190-BIB62|cit62","unstructured":"Gauthier S Feldman H Vellas B Subbiah P Efficacy of donepezil on functional, behavioural and cognitive symptoms in patients with moderate to severe alzheimer's disease Journal of the American Geriatrics Society 2000 S2"},{"key":"10.1002\/14651858.CD001190-BIB63|cit63","doi-asserted-by":"crossref","unstructured":"Hecker J Foti D Gauthier S Vellas B Subbiah P Whalen E Benefits of Donepezil in the treatment of behavioural problems in moderate to severe Alzheimer's Disease Proceedings of the World Alzheimer Congress; 2000 Jul 9-13, Washington DC 2000","DOI":"10.1016\/S0197-4580(00)82066-7"},{"key":"10.1002\/14651858.CD001190-BIB64|cit64","doi-asserted-by":"crossref","unstructured":"Luckmann R Donepezil improved the clinical state and quality of life in moderate-to-severe Alzheimer disease ACP-Journal-Club 2002 59","DOI":"10.7326\/ACPJC-2002-136-2-059"},{"key":"10.1002\/14651858.CD001190-BIB65|cit65","doi-asserted-by":"crossref","unstructured":"Panisset M Feldman H Gauthier S Hecker J Vellas B Subbiah P Whalen E Use of the severe impairment battery in a clinical trial of Donepezil in moderate to severe Alzheimers Disease Proceedings of the World Alzheimer Congress; 2000 Jul 9-13, Washington 2000","DOI":"10.1016\/S0197-4580(00)82648-2"},{"key":"10.1002\/14651858.CD001190-BIB66|cit66","doi-asserted-by":"crossref","unstructured":"Vellas B Feldman H Gauthier S Hecker J Subbiah P Whalen E Mastey V Donepezil treatment in patients with moderate to severe Alzheimer's Disease reduces caregiver stress Proceedings of the World Alzheimer Congress; 2000 Jul 9-13, Washington 2000","DOI":"10.1016\/S0924-977X(00)80473-3"},{"key":"10.1002\/14651858.CD001190-BIB67|cit67","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1001\/archneur.57.1.94","article-title":"Donepezil therapy in clinical practice: a randomized crossover study","volume":"57","author":"Meadows","year":"2000","journal-title":"Arch Neurol"},{"key":"10.1002\/14651858.CD001190-BIB68|cit68","doi-asserted-by":"crossref","unstructured":"Engedal K Soininen H Verhey F Waldemar G Winblad B Wimo A Wetterholm AL Zhang R Haglund A Subbiah P Donepezil improved or stabilized cognition over one year in patients with mild and moderate alzheimer's disease Journal of the European College of Neuropsychopharmacology 2000 S368 SR-HANDSRCH","DOI":"10.1016\/S0924-977X(00)80492-7"},{"key":"10.1002\/14651858.CD001190-BIB69|cit69","doi-asserted-by":"crossref","unstructured":"Mastey V Wimo A Winblad B Haglund A Jacobson L Miceli R Zhang R Subbiah P An economic evaluation of donepezil in mild to moderate alzheimer's disease: results of a one year, double-blind, randomized trial Journal of the American Geriatrics Society 2001 S131","DOI":"10.1016\/S0197-4580(00)82504-X"},{"key":"10.1002\/14651858.CD001190-BIB70|cit70","unstructured":"Mastey V Wimo A Winblad B Haglund A Jacobson L Miceli R Zhang R Subbiah P Donepezil reduces the time caregivers spend providing care: results of a one-year, double-blind, randomized trial in patients with mild to moderate Alzheimer's disease Proceedings of the 14th Annual Meeting of the American Association for Geriatric Psychiatry; 2001 Feb 23-26, San Francisco 2001"},{"key":"10.1002\/14651858.CD001190-BIB71|cit71","doi-asserted-by":"crossref","unstructured":"Soininen H Winblad B Engedal K Verhey F Waldemar G Wimo A Wetterholme AL Zhang R Hugland A Subbiah P Long term benefits of donepezil on ADLs in AD patients Proceedings of the Annual Scientific Meeting of the American Geriatric Society and the American Federation for Aging Research; 2000 May 17-21, Nashville 2000 171","DOI":"10.1016\/S0197-4580(00)82062-X"},{"key":"10.1002\/14651858.CD001190-BIB72|cit72","doi-asserted-by":"crossref","unstructured":"Soininen H, Winblad B, Engedal K, Verhey F, Waldemar G, Wimo A, Zhang R, Subbiah P, Donepezil Nordic Study Group Response to Donepezil is not predicted by apolipoprotein E genotype and\/or gender Proceedings of the World Alzheimer Congress; 2000 Jul 9-13, Washington 2000","DOI":"10.1016\/S0197-4580(00)82062-X"},{"key":"10.1002\/14651858.CD001190-BIB73|cit73","doi-asserted-by":"crossref","unstructured":"Waldemar G, Winblad B, Engedal K, Soininen H, Donepezil Nordic Study Group Benefits of Donepezil on cognition, function and\/or neuropsychiatric symtoms in patients with Alzheimers Disease over one year Proceedings of the World Alzheimer Congress; 2000 Jul 9-13, Washington DC 2000","DOI":"10.1016\/S0197-4580(00)83186-3"},{"key":"10.1002\/14651858.CD001190-BIB74|cit74","unstructured":"Waldemar G, Winblad B, Engedal K, Soininen HS, Verhey FR, Wimo A, Wetterholm AL, Zhang R, Haglund AA, Subbiag P, Donepezil Nordic Study Group Donepezil benefits patients with either mild of moderate Alzheimer's disease over one year Neurology 2000 A470"},{"key":"10.1002\/14651858.CD001190-BIB75|cit75","doi-asserted-by":"crossref","unstructured":"Wimo A Winblad B Mastey V An economic evaluation of Donepezil in mild to moderate Alzheimers Disease: Results of a one-year, double-blind, randomized trial Proceedings of the World Alzheimer Congress; 2000 Jul 9-13, Washington DC 2000","DOI":"10.1016\/S0197-4580(00)82504-X"},{"key":"10.1002\/14651858.CD001190-BIB76|cit76","doi-asserted-by":"crossref","unstructured":"Wimo A Winblad B Mastey V Haglund A Hertzman P Miceli R Jacobson L Subbiah P An economic evaluation of donepezil in mild to moderate alzheimer's disease patients: results of a one-year, double-blind, randomized trial Proceedings of the 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13-18, Chicago, Illionois 2000 SR-HANDSRCH","DOI":"10.1016\/S0197-4580(00)82504-X"},{"key":"10.1002\/14651858.CD001190-BIB77|cit77","unstructured":"Winblad B Long term therapeutic benefits of acetylcholinesterase inhibitor therapy in patients with alzheimer's disease Proceedings of the Sixth International Stockholm\/Springfield Symposium on Advances in Alzheimer Therapy; 2000 Apr 5-8, Stockholm 2000 164"},{"key":"10.1002\/14651858.CD001190-BIB78|cit78","doi-asserted-by":"crossref","unstructured":"Winblad B Engedal K Soininen H Verhey F Waldemar G Wimo A Wetterholm A Zhang R Haglund A Subbiah P A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD Neurology 2001 489 95","DOI":"10.1212\/WNL.57.3.489"},{"issue":"Supplement 1","key":"10.1002\/14651858.CD001190-BIB79|cit79","first-page":"138","article-title":"Donepezil enhances global function, cognition and activities of daily living compared with placebo in a one-year, double-blind trial in patients with mild to moderate Alzheimer's disease","volume":"11","author":"Winblad","year":"1999","journal-title":"International Psychogeriatrics"},{"key":"10.1002\/14651858.CD001190-BIB80|cit80","unstructured":"Winblad B Engedal K Soininen H Verhey F Waldemar G Wimo A Wetterholm AL Zhang R Haglund A Subbiah P Donepezil enhances global function and acitivities of daily living compared with placebo in a one-year, double-blind trial in patients with mild to moderate alzheimer's disease Proceedings of the Quality Research in Dementia Conference; 2000 Nov 19-22, London 2000"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD001190-BIB81|cit81","first-page":"5175(PW11017)","article-title":"Donepezil provides long term benefits for patients with Alzheimer's disease","volume":"2","author":"Friedhoff","year":"1999","journal-title":"International Journal of Psychopharmacology"},{"key":"10.1002\/14651858.CD001190-BIB82|cit82","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/S0022-510X(97)86335-6","article-title":"Donepezil provides long-term clinical benefits for patients with Alzheimer's disease (AD)","volume":"150","author":"Rogers","year":"1997","journal-title":"International Journal of Neurological Sciences"},{"key":"10.1002\/14651858.CD001190-BIB83|cit83","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0924-977X(97)00079-5","article-title":"Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study","volume":"8","author":"Rogers","year":"1998","journal-title":"European Neuropsychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD001190-BIB84|cit84","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/0924-977X(95)90701-E","article-title":"Clinical benefits are maintained during long-term treatment of Alzheimer's disease with the acetylcholinesterase inhibitor E2020","volume":"5","author":"Rogers","year":"1995","journal-title":"European Journal of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD001190-BIB85|cit85","unstructured":"Ames D Boada M Sakka P Triau E Turcani P Vagenas V Bahra R Zhang R Efficacy and tolerability of donepezil in patients with alzheimer's disease: findings from a large multinational experience study Proceedings of the 17th Alzheimer's Disease International Conference; 2001 Oct 25-27, Christchurch, New Zealand 2001 181"},{"key":"10.1002\/14651858.CD001190-BIB86|cit86","doi-asserted-by":"crossref","unstructured":"Barak Y Bodner E Zemishlani H Mirecki I Aizenberg D Donepezil for the treatment of behavioral disturbances in Alzheimer's disease: a 6-month open trial Archives of Gerontology and Geriatrics 2001 237 41","DOI":"10.1016\/S0167-4943(01)00187-X"},{"key":"10.1002\/14651858.CD001190-BIB87|cit87","doi-asserted-by":"crossref","unstructured":"Berger E Sramko CA Fr\u00f6lich L Calabrese P Donepezil provides relevant theraputic benefits in different domalns to real world patients with Alzheimer's disease The 12th ENCP Congress European neuropsychopharmacology, London, 2000 2000 369","DOI":"10.1016\/S0924-977X(00)80494-0"},{"key":"10.1002\/14651858.CD001190-BIB88|cit88","doi-asserted-by":"crossref","unstructured":"Sramko CA Berger F Calabrese P Fr\u00f6lich L Tolerability and safety of donepezil in the treatment of Alzheimer's disease results from a post marketing surveillance study The 12th ENCP Congress European neuropsychopharmacology, London, 2000 2000 368","DOI":"10.1016\/S0924-977X(00)80493-9"},{"key":"10.1002\/14651858.CD001190-BIB89|cit89","unstructured":"Birt AR Fay S Graham JE Rockwood K Recovery of intention as a noverl effect on traeting Alzheimer's disease with donepezil The 8th conference on Alzheimer's disease and related disorders, July 20-25, 2002, Stockholm, Sweden 2002 595"},{"key":"10.1002\/14651858.CD001190-BIB90|cit90","doi-asserted-by":"crossref","unstructured":"Borroni B Colciaghi F Pastorino L Pettenati C Cottini E Rozzini L Monastero R Lenzi GL Cattabeni F Di Luca M Padovani A Amyloid precursor protein in platelets of patients with Alzheimer disease: Effect of acetylcholinesterase inhibitor treatment Archives of Neurology 2001 442 6","DOI":"10.1001\/archneur.58.3.442"},{"key":"10.1002\/14651858.CD001190-BIB91|cit91","unstructured":"Boundy K, Brodaty H, Australian Donepezil Study Group, Barrington M, O'Leary M, Short K, Bahra R, Zhang R Eficacy of donepezil in patients with alzheimer's disease: findings from the autralian subset of a large multinational experience study Proceedings of the 17th Alzheimer's Disease International Conference; 2001 Oct 25-27, Christchurch, New Zealand 2001"},{"key":"10.1002\/14651858.CD001190-BIB92|cit92","doi-asserted-by":"crossref","unstructured":"Brodaty H Bahara R Zhang R O'Leary M Short K Barrington M Efficacy and safety of donepezil in patients with Alzheimer's disease preliminary findings from the Australian subset of a global clinical experience study Journal of the European College of Neuropsychopharmacology 2000 S367","DOI":"10.1016\/S0924-977X(00)80490-3"},{"key":"10.1002\/14651858.CD001190-BIB93|cit93","doi-asserted-by":"crossref","unstructured":"Bullock RA Voss SE The clinical utility of Donepezil: From randomized clinical trials to practice Proceedings of the World Alzheimer Congress; 2000 Jul 9-13, Washington 2000","DOI":"10.1016\/S0197-4580(00)82083-7"},{"key":"10.1002\/14651858.CD001190-BIB94|cit94","unstructured":"Bullock R Passmore F Potocnik F Hock C The tolerability, ease of use and efficacy of donepezil and rivastigmine in alzeimer's disease patients: a 12-week, multinational, comparative study Journal of the American Geriatrics Society 2001 S19"},{"key":"10.1002\/14651858.CD001190-BIB95|cit95","doi-asserted-by":"crossref","unstructured":"Bullock R Wilkinson DG Passmore P Hopker SW Smith R Potocnik FC Maud CM Hock C Caregiver and physician determination of satisfaction with and ease of use of donepezil and rivastigamine treatment in alzheimer's disease patients Proceedings of the 17th Alzheimer's Disease International Conference; 2001 Oct 25-27, Christchurch, New Zealand 2001 39","DOI":"10.1016\/S0924-977X(01)80453-3"},{"key":"10.1002\/14651858.CD001190-BIB96|cit96","unstructured":"B\u00f6ttcher-Buhler E [Well tolerated, effective and inexpensive therapy of Alzheimer's dementia with donepezil] Neurologie und Rehabilitation 2000 332 3"},{"key":"10.1002\/14651858.CD001190-BIB97|cit97","doi-asserted-by":"crossref","unstructured":"Potocnik FC Smith R Passmore P Hock C Wilkinson D Maud CM Hopker S Tolerability, ease of use, and efficacy of donepezil and rivastigmine in alzheimer's disease patients Proceedings of the Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans 2001","DOI":"10.1016\/S0924-977X(01)80453-3"},{"key":"10.1002\/14651858.CD001190-BIB98|cit98","doi-asserted-by":"crossref","unstructured":"Wilkinson D Passmore P Potocnik F Maud C Hock C Donepezil compared to rivastigmine in Alzheimer's disease: similar efficacy but better tolerability and physician and caregiver satisfaction in a multinational randomized trial Proceedings of the 14th Annual Meeting of the American Association for Geriatric Psychiatry; 2001 Feb 23-26, San Francisco 2001","DOI":"10.1016\/S0924-977X(01)80453-3"},{"key":"10.1002\/14651858.CD001190-BIB99|cit99","doi-asserted-by":"crossref","unstructured":"Cameron I Curran S Newton P Petty D Wattis J Use of donepezil for the treatment of mild-moderate Alzheimer's disease: An audit of the assessment and treatment of patients in routine clinical practice International Journal of Geriatric Psychiatry 2000 887 91","DOI":"10.1002\/1099-1166(200010)15:10<887::AID-GPS212>3.0.CO;2-M"},{"key":"10.1002\/14651858.CD001190-BIB100|cit100","unstructured":"Clary C McRae T Griesing T Whalen E The safety of donepezil and sertraline for the management of behavioral symptoms in patients with Alzheimer's disease International Journal of Neuropsychopharmacology 2000 S267 SR-HANDSRCH"},{"key":"10.1002\/14651858.CD001190-BIB101|cit101","unstructured":"Finkel S McRae T Burt T Sertraline and donepezil demonstrate greater efficacy and similar tolerability compared to donepezil alone in non-depressed patients with Alzheimer's disease Proceedings of the 14th Annual Meeting of the American Association for Geriatric Psychiatry; 2001 Feb 23-26, San Francisco 2001"},{"key":"10.1002\/14651858.CD001190-BIB102|cit102","doi-asserted-by":"crossref","unstructured":"McRae T Griesing T Whalen E Effectiveness of Donepezil on behavioural disturbances in mild to moderate Alzheimer's Disease patients Proceedings of the World Alzheimer Congress; 2000 Jul 9-13, Washington 2000","DOI":"10.1016\/S0197-4580(00)82644-5"},{"key":"10.1002\/14651858.CD001190-BIB103|cit103","unstructured":"McRae T Griesing T Whalen E Donepezil and sertraline for the management of behavioral symptoms in patients with alzheimer's disease Neurology 2000 A416 7"},{"key":"10.1002\/14651858.CD001190-BIB104|cit104","series-title":"Proceedings of the Annual Scientific Meeting of the American Geriatric Society and the American Federation for Aging Research; 2000 May 17-21, Nashville","first-page":"173","article-title":"Managing behaviour symptoms in patients withalzheimer's disease (AD)","author":"Mcrae","year":"2000"},{"key":"10.1002\/14651858.CD001190-BIB105|cit105","doi-asserted-by":"crossref","unstructured":"Cummings JL Donohue JA Brooks RL The relationship between donepezil and behavioral disturbances in patients with Alzheimer's disease American Journal of Geriatric Psychiatry 2000 134 40","DOI":"10.1097\/00019442-200005000-00008"},{"key":"10.1002\/14651858.CD001190-BIB106|cit106","unstructured":"Fillit H Hill JW Futtertman R Mastery V Sustained donepezil therapy reduces healthcare costs in Alzheimer's disease The 8th conference on Alzheimer's disease and related disorders, July 20-25, 2002, Stockholm, Sweden 2002 192"},{"key":"10.1002\/14651858.CD001190-BIB107|cit107","doi-asserted-by":"crossref","unstructured":"Fuschillo C La Pia S Campana F Pinto A De Simone L Cognitive deficits in alzheimer's disease: treatment with acetylcholinesterase inhibitor agents Archives of Gerontology and Geriatrics 2001 151 8","DOI":"10.1016\/S0167-4943(01)00134-0"},{"key":"10.1002\/14651858.CD001190-BIB108|cit108","doi-asserted-by":"crossref","unstructured":"Hampel H Berger F Froelich L Switching from other antidementive therapies to donepezil (aricept \u00ae ): improvement of quality of life of alzheimer patients in routine clinical use The International Symposium on advances in Alzheimer therapy, 2002, geneva 2002 198","DOI":"10.1016\/S0924-977X(02)80625-3"},{"key":"10.1002\/14651858.CD001190-BIB109|cit109","first-page":"185","article-title":"Late phase II clinical study of acetylcholinesterase inhibitor E2020 in patients with Alzheimer-type dementia","volume":"26","author":"Homma","year":"1998","journal-title":"Clinical Evaluation"},{"key":"10.1002\/14651858.CD001190-BIB110|cit110","first-page":"209","article-title":"Late phase II clinical study of acetylcholinesterase inhibitor E2020 in patients with Alzheimer-type dementia","volume":"26","author":"Homma","year":"1998","journal-title":"Clinical Evaluation"},{"key":"10.1002\/14651858.CD001190-BIB111|cit111","first-page":"145","article-title":"Early phase II clinical study of acetylcholinesterase inhibitor E2020 in patients with Alzheimer-type dementia","volume":"26","author":"Imai","year":"1998","journal-title":"Clinical Evaluation"},{"key":"10.1002\/14651858.CD001190-BIB112|cit112","first-page":"165","article-title":"Early phase II clinical study of acetylcholinesterase inhibitor E2020 in patients with Alzheimer-type dementia","volume":"26","author":"Imai","year":"1998","journal-title":"Clinical Evaluation"},{"key":"10.1002\/14651858.CD001190-BIB113|cit113","first-page":"233","article-title":"Late phase II clinical study of acetylcholinesterase inhibitor E2020 in patients with Alzheimer-type dementia","volume":"26","author":"Imai","year":"1998","journal-title":"Clinical Evaluation"},{"key":"10.1002\/14651858.CD001190-BIB114|cit114","unstructured":"Kauffer D Catt K Pollock B DeKosky S Assessing the effects of donepezil in alzheimer's patients and its impact on caregivers Journal of the American Geriatrics Society 1998 S66"},{"key":"10.1002\/14651858.CD001190-BIB115|cit115","unstructured":"Leube D Grodd W Erb M Henning W Bartels M Kircher T Task related cortical areas are differentially activated in pateints with Alzheimers' disease after a ten week treatment with donezepil The 8th conference on Alzheimer's disease and related disorders, July 20-25, 2002, Stockholm, Sweden 2002 1548"},{"key":"10.1002\/14651858.CD001190-BIB116|cit116","unstructured":"Maltz J Eberling J Jagust w Budinger T Donepezil therapy enhancse methacholine induced cutaneous vasodilation in Alzheimer's disease patients The 8th conference on Alzheimer's disease and related disorders, July 20-25, 2002, Stockholm, Sweden 2002 318"},{"key":"10.1002\/14651858.CD001190-BIB117|cit117","doi-asserted-by":"crossref","unstructured":"Matthews HP Korbey J Wilkinson DG Rowden J Donepezil in Alzheimer's disease: eighteen month results from Southampton Memory Clinic International Journal of Geriatric Psychiatry 2000 713 20","DOI":"10.1002\/1099-1166(200008)15:8<713::AID-GPS187>3.0.CO;2-I"},{"key":"10.1002\/14651858.CD001190-BIB118|cit118","unstructured":"McRae T Orazem J A large, community-based trial of donepezil in the treatment of alzheimer's disease (AD) Journal of the American Geriatrics Society 1999 S63"},{"key":"10.1002\/14651858.CD001190-BIB119|cit119","doi-asserted-by":"crossref","unstructured":"McRae T Knopman D Duttagupta S Ieni J Provenzano G Donepezil delays time to nursing home placement in patients with Alzheimer's disease Proceedings of the 14th Annual Meeting of the American Association for Geriatric Psychiatry; 2001 Feb 23-26, San Francisco 2001","DOI":"10.1046\/j.1524-4733.2001.40202-235.x"},{"key":"10.1002\/14651858.CD001190-BIB120|cit120","unstructured":"McRae T Knopman D Mastey V Ieni J Provenzano G Donepezil is strongly associated with delayed nursing home placement in patients with alzheimer's disease Journal of Neuroscience 2001 S536"},{"key":"10.1002\/14651858.CD001190-BIB121|cit121","doi-asserted-by":"crossref","unstructured":"Mega MS Masterman DM O'Connor SM Barclay TR Cummings JL The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease Archives of Neurology 1999 1388 93","DOI":"10.1001\/archneur.56.11.1388"},{"key":"10.1002\/14651858.CD001190-BIB122|cit122","unstructured":"Mega MS Manese M Felix J Tran N O'Connor Sm Masterman DM toga Aw Cummings JL Laboratory of neuro imaging Alzheimer's disease Anterior cingulate activation occurs across cholinesterase inhibitor thepapy in Alzheimer's disease The 10th congress of the international psychogeriatric association, Nice, France, September 9-14, 2001 2001 S108"},{"key":"10.1002\/14651858.CD001190-BIB123|cit123","unstructured":"Mega M Dinov I Manese M Felix J O'Connor S Toga A Cummings J Cerebral metabolic activation with cholinesterase inhibitor therapy in Alzheimer's disease The 8th conference on Alzheimer's disease and related disorders, July 20-25, 2002, Stockholm, Sweden 2002 430"},{"key":"10.1002\/14651858.CD001190-BIB124|cit124","unstructured":"Nikolova G Traykov L Efficacy of donepezil in patients with alzheimer's disease - results of 12-week open clinical trial Acta Medica Bulgarica 2001 70 5"},{"key":"10.1002\/14651858.CD001190-BIB125|cit125","doi-asserted-by":"crossref","unstructured":"Parsa MA Poggi E Barte L Treatment of dementia patients with psychotic and behavioural symptoms with quetiapine and donepezil Journal of the European College of Neuropsychopharmacology 2000 S302 SR-HANDSRCH","DOI":"10.1016\/S0924-977X(00)80339-9"},{"key":"10.1002\/14651858.CD001190-BIB126|cit126","unstructured":"Peng D Xu X Hou Q The safety and efficacy of aricept in patients with alzheimer disease Chinese Journal of Neurology 2002 19 21"},{"key":"10.1002\/14651858.CD001190-BIB127|cit127","doi-asserted-by":"crossref","unstructured":"Rocca P Cocuzza E Marchiaro L Bogetto F Donepezil in the treatment of alzheimer's disease: long-term efficacy and safety Progress in Neuro Psychopharmacology and Biological Psychiatry 2002 369 73","DOI":"10.1016\/S0278-5846(01)00283-4"},{"key":"10.1002\/14651858.CD001190-BIB128|cit128","unstructured":"Rockwood K Graham J Fay S Translating from regulatory measures to patients' daily lives an analysis of alzheimer's disease treatment with donepezil The 8th conference on Alzheimer's disease and related disorders, July 20-25, 2002, Stockholm, Sweden 2002 2034"},{"key":"10.1002\/14651858.CD001190-BIB129|cit129","doi-asserted-by":"crossref","unstructured":"Rodriguez G Vitali P De Leo C De Cadi F Girtler N Nobili F Quantitative EEG changes in alzheimer patients during long-term donepezil therapy The International Symposium on advances in Alzheimer therapy, 2002, geneva 2002 239","DOI":"10.1159\/000063576"},{"key":"10.1002\/14651858.CD001190-BIB130|cit130","doi-asserted-by":"crossref","unstructured":"Rogers SL Friedhoff LT Donepezil is well tolerated at clinically effective doses for the treatment of Alzheimer's disease (AD) Proceedings of the 10th European College of Neuropsychopharmacology Congress; 1997 Sep 13-17, Vienna, Austria 1997 SR-HANDSRCH","DOI":"10.1016\/S0924-977X(97)88830-X"},{"key":"10.1002\/14651858.CD001190-BIB131|cit131","series-title":"The 8th conference on Alzheimer's disease and related disorders, July 20-25, 2002, Stockholm, Sweden","first-page":"329","article-title":"Acetylcholinesterase inhibitors are effective in real world patients with mild to moderate Alzheimer disease evidence from a large population treated with rivastigmine or donepezil","author":"Rozzini","year":"2002"},{"key":"10.1002\/14651858.CD001190-BIB132|cit132","series-title":"The 8th conference on Alzheimer's disease and related disorders, July 20-25, 2002, Stockholm, Sweden","first-page":"240","article-title":"Comparison of efficacy and safety of rivastigmine and donepezil in patients with mild to moderate alzheimer disease: results from a multicentre randomised trial","author":"Rozzini","year":"2002"},{"key":"10.1002\/14651858.CD001190-BIB133|cit133","unstructured":"Shua-Haim J Smith J Amin S Shua-Haim V Comparison of combinition therapy with rivastigmine exelon and donepezil aricept versus rivastigmine alone for treatment of Alzheimer's disease safety tolerability and clinical experiance after one year of treatment a cross section study The 8th conference on Alzheimer's disease and related disorders, July 20-25, 2002, Stockholm, Sweden 2002 292"},{"key":"10.1002\/14651858.CD001190-BIB134|cit134","unstructured":"Shua-Haim J Smith J Potel S A head to study of donepezitl aricept rivastigmine exlon and galantamine reminyl for the treatment of Alzheimer's disease safety tolerability clinical and caregiver impression after 4-5 months of trratment a prospective study The 8th conference on Alzheimer's disease and related disorders, July 20-25, 2002, Stockholm, Sweden 2002 286"},{"key":"10.1002\/14651858.CD001190-BIB135|cit135","doi-asserted-by":"crossref","unstructured":"Stewart A Phillips R Dempsey G Pharmacotherapy for people with Alzheimer's disease: A Markov-cycle evaluation of five years' therapy using donepezil International Journal of Geriatric Psychiatry 1998 445 53","DOI":"10.1002\/(SICI)1099-1166(199807)13:7<445::AID-GPS794>3.0.CO;2-E"},{"key":"10.1002\/14651858.CD001190-BIB136|cit136","unstructured":"Tessitore A Iavarone A Tessitore A Donepezil in the treatment of mild to moderate Alzheimer's disease: Follow-up at 12 months in 40 treated patients Nuova Rivista di Neurologia 2000 183 6"},{"key":"10.1002\/14651858.CD001190-BIB137|cit137","doi-asserted-by":"crossref","unstructured":"Tettamanti M Casilli D Baldinetti F Apollonio I Ruffo P Nobili A Riva E Lucca U Donepezil Italian Global Impact Study (DIGIS) Proceedings of the World Alzheimer Congress; 2000 Jul 9-13, Washington DC 2000","DOI":"10.1016\/S0197-4580(00)83415-6"},{"key":"10.1002\/14651858.CD001190-BIB138|cit138","doi-asserted-by":"crossref","unstructured":"Thomas A Iacono D Bonanni L D' Andreamatteo G Onofrj M Donepezil, rivastigmine,and vitamine E in Alzheimer disease: A combined P300 event-related potentials\/neuropsychologic evaluation over 6 months Clinical Neuropharmacology 2001 31 42","DOI":"10.1097\/00002826-200101000-00007"},{"key":"10.1002\/14651858.CD001190-BIB139|cit139","unstructured":"Tsolaki M Gerothanassis D Aristotle CP Efficacy and safety of cholinesterase inhibitors a longitudinal comparative study between donepezil and rivastigmine The 8th conference on Alzheimer's disease and related disorders, July 20-25, 2002, Stockholm, Sweden 2002 2038"},{"key":"10.1002\/14651858.CD001190-BIB140|cit140","doi-asserted-by":"crossref","unstructured":"Vanmechelen E Andreasen N Minthon L Davidsson P Amici S Gallai V Parnetti L Pottel H Blennow K Effects of cholinesterase inhibitors on alzheimer disease biomarkers Proceedings of the 7th International Geneva\/Springfield Symposium on Advances in Alzheimer therapy, 2002 Apr 3-6, Geneva 2002 252","DOI":"10.1007\/s100720200086"},{"key":"10.1002\/14651858.CD001190-BIB141|cit141","doi-asserted-by":"crossref","unstructured":"Weiner MF Martin-Cook K Foster BM Saine K Fontaine CS Svetlik DA Effects of donepezil on emotional\/behavioral symptoms in Alzheimer's disease patients Journal of Clinical Psychiatry 2000 487 92","DOI":"10.4088\/JCP.v61n0705"},{"key":"10.1002\/14651858.CD001190-BIB142|cit142","unstructured":"Werber EA Klein C Rabey MJ Evaluation of cholinergic treatment in demented by p300 evoked related potentials The 8th conference on Alzheimer's disease and related disorders, July 20-25, 2002, Stockholm, Sweden 2002 442"},{"key":"10.1002\/14651858.CD001190-BIB143|cit143","unstructured":"Ongoing study"},{"key":"10.1002\/14651858.CD001190-BIB144|cit144","unstructured":"Anon Double-blind trial will compare two anti-alzheimer's drugs Journal of Dementia Care 2001 6"},{"key":"10.1002\/14651858.CD001190-BIB145|cit145","unstructured":"AWARE (Aricept Washout and Rechallenge) Ongoing study"},{"key":"10.1002\/14651858.CD001190-BIB146|cit146","unstructured":"Johannsen P, Barcikowska M, Hasselbalch S, Ihl R, Karageorgiou C, Nunez M, Salmon E, Trixler M, Qvitzau S, Johansen L, Emir B, Subbiah P, The AWARE Study Group Results from the pre-randomization phase of the donepezil aware study further understanding the meaning of clinical benefit Proceedings of the 7th International Geneva\/Springfield Symposium on Advances in Alzheimer therapy, 2002 Apr 3-6, Geneva 2002 201"},{"key":"10.1002\/14651858.CD001190-BIB147|cit147","unstructured":"Ongoing study"},{"key":"10.1002\/14651858.CD001190-BIB148|cit148","unstructured":"Anon Study of Donepezil in patients with mild to moderate Alzheimer's Disease Centerwatch"},{"key":"10.1002\/14651858.CD001190-BIB149|cit149","unstructured":"Ongoing study"},{"key":"10.1002\/14651858.CD001190-BIB150|cit150","unstructured":"Gauthier S Lussier I Donepezil treatment is associated with alleviation of caregiver burden in alzheimer's disease: interim results from an open-label multicentre clinical trial European Journal of Neurology 1999 116 SR-HANDSRCH"},{"key":"10.1002\/14651858.CD001190-BIB151|cit151","unstructured":"Ongoing study"},{"key":"10.1002\/14651858.CD001190-BIB152|cit152","unstructured":"Haworth J Comparison of Aricept and Galantamine (Reminyl) in Alzheimer's disease National Research Register 2000"},{"key":"10.1002\/14651858.CD001190-BIB153|cit153","unstructured":"Ongoing study"},{"key":"10.1002\/14651858.CD001190-BIB154|cit154","unstructured":"Holmes C Non-cognitive symptoms and response to Donepezil National Research Register 2000"},{"key":"10.1002\/14651858.CD001190-BIB155|cit155","unstructured":"Pandita-Gunawardena D Non-cognitive symptoms and response to Donepezil National research Register 2001"},{"key":"10.1002\/14651858.CD001190-BIB156|cit156","unstructured":"Ongoing study"},{"key":"10.1002\/14651858.CD001190-BIB157|cit157","unstructured":"Lindesay J A study into the effects of Donepezil on non-cognitive symptoms in patients with Alzheimer's disease and the clinical characteristics of responders National Research Register 2000"},{"key":"10.1002\/14651858.CD001190-BIB158|cit158","unstructured":"Ongoing study"},{"key":"10.1002\/14651858.CD001190-BIB159|cit159","unstructured":"Memory Disorders Study Unit An open-label, multicentre, extended evaluation of the safety and efficacy of E2020 in patients with Alzheimer's Disease South Australian Network For Research On Ageing (SANRA) 2000"},{"key":"10.1002\/14651858.CD001190-BIB160|cit160","unstructured":"Ongoing study"},{"key":"10.1002\/14651858.CD001190-BIB161|cit161","unstructured":"O'Brien A A pilot study comparing the effect of galantamine (Reminyl) with donepezil in patients with Alzheimer's Disease National Research Register 2000"},{"key":"10.1002\/14651858.CD001190-BIB162|cit162","unstructured":"Ongoing study"},{"key":"10.1002\/14651858.CD001190-BIB163|cit163","unstructured":"Salloway S A double blind randomized pilot study to evaluate the effects of galantamine and donepezil on sleep and attention and gastrointestinal GI tolerance in patients with mild to moderate Alzheimer's disease AD Clinical Trials.gov 2002 1 2"},{"key":"10.1002\/14651858.CD001190-BIB164|cit164","unstructured":"Ongoing study"},{"key":"10.1002\/14651858.CD001190-BIB165|cit165","unstructured":"Thompson SB A Qualitative Analysis of the Outcomes of Aricept Use in Community Settings National Research Register 1999 http:\/\/www.doh.gov.uk\/nrr.htm"},{"key":"10.1002\/14651858.CD001190-BIB166|cit166","unstructured":"Ongoing study"},{"key":"10.1002\/14651858.CD001190-BIB167|cit167","unstructured":"Wahby CT Effects of Donepezil on vascular and Alzheimer types of dementia National Research Register 2000 http:\/\/www.doh.gov.uk\/nrr.htm"},{"key":"10.1002\/14651858.CD001190-BIB168|cit168","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"1987"},{"key":"10.1002\/14651858.CD001190-BIB169|cit169","first-page":"637","article-title":"Clinical Dementia Rating (CDR)","volume":"24","author":"Berg","year":"1988","journal-title":"Psychopharm Bull"},{"key":"10.1002\/14651858.CD001190-BIB170|cit170","first-page":"464","article-title":"Quality of life, social indicators and criteria of change","volume":"8","author":"Blau","year":"1977","journal-title":"Prof Psychol"},{"key":"10.1002\/14651858.CD001190-BIB171|cit171","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1056\/NEJM198312013092204","article-title":"Bias in Treatment Assignment in Controlled Clinical Trials","volume":"309","author":"Chalmers","year":"1983","journal-title":"N Eng J Med"},{"key":"10.1002\/14651858.CD001190-BIB172|cit172","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1212\/WNL.44.12.2308","article-title":"The neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia","volume":"44","author":"Cummings","year":"1994","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD001190-BIB173|cit173","first-page":"545","article-title":"Measurement of quality-of-life changes in patients with Alzheimer's disease","volume":"11","author":"DeJong","year":"1989","journal-title":"Clin Ther"},{"key":"10.1002\/14651858.CD001190-BIB174|cit174","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J Psychiatr Res"},{"key":"10.1002\/14651858.CD001190-BIB175|cit175","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/0167-4943(82)90031-0","article-title":"A new rating scale for dementia syndromes","volume":"1","author":"Gottfries","year":"1982","journal-title":"Arch Gerontol Geriatr"},{"key":"10.1002\/14651858.CD001190-BIB176|cit176","doi-asserted-by":"crossref","first-page":"471","DOI":"10.5014\/ajot.53.5.471","article-title":"Development of a functional measure for persons with Alzheimer's disease: the Disability Assessment for Dementia","volume":"53","author":"G\u00e9linas","year":"1999","journal-title":"American Journal of Occupational Therapy"},{"key":"10.1002\/14651858.CD001190-BIB177|cit177","first-page":"1217","article-title":"Development of a new rating scale for dementia in the elderly: Mental Function Impairment Scale (MENFIS)","volume":"2","author":"Homma","year":"1991","journal-title":"Journal of Geriatric Psychiatry"},{"key":"10.1002\/14651858.CD001190-BIB178|cit178","volume-title":"The ICD-10 classification of mental and behavioural disorders: clinical description and diagnostic guidelines","year":"1992"},{"key":"10.1002\/14651858.CD001190-BIB179|cit179","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomised clinical trials: Is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Controlled Clin Trials"},{"key":"10.1002\/14651858.CD001190-BIB180|cit180","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/geront\/9.3_Part_1.179","article-title":"Assessment of older people: Self-maintaining and instrumental activities of daily living","volume":"9","author":"Lawton","year":"1969","journal-title":"Gerontologist"},{"key":"10.1002\/14651858.CD001190-BIB181|cit181","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical Diagnosis of Alzheimer\u2019s Disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s Disease","volume":"4","author":"McKhann","year":"1984","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD001190-BIB182|cit182","article-title":"Cochrane Collaboration Handbook [updated 9 December 1996].","volume-title":"Available in The Cochrane Library [database on disk and CDROM]. The Cochrane Collaboration; Issue 1","author":"Mulrow","year":"1997"},{"key":"10.1002\/14651858.CD001190-BIB183|cit183","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1176\/ajp.141.11.1356","article-title":"A new rating scale for Alzheimer's disease","volume":"141","author":"Rosen","year":"1984","journal-title":"Am J Psychiatry"},{"key":"10.1002\/14651858.CD001190-BIB184|cit184","volume-title":"CAMDEX: The Cambridge Examination for Mental Disorders of the Elderly","author":"Roth","year":"1988"},{"issue":"suppl 2","key":"10.1002\/14651858.CD001190-BIB185|cit185","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1097\/00002093-199700112-00004","article-title":"Validity and reliability of the Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change","volume":"11","author":"Schneider","year":"1997","journal-title":"AD Assoc Dis"},{"key":"10.1002\/14651858.CD001190-BIB186|cit186","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"}],"updated-by":[{"DOI":"10.1002\/14651858.cd001190.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2006,1,25]],"date-time":"2006-01-25T00:00:00Z","timestamp":1138147200000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD001190","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T13:58:46Z","timestamp":1682603926000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD001190"}},"subtitle":[],"editor":[{"given":"Jacqueline","family":"Birks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2003,7,21]]},"references-count":186,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd001190","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD001190.pub2","asserted-by":"object"}]},"subject":[],"published":{"date-parts":[[2003,7,21]]}}}